Arrowhead Pharmaceuticals opened lower at $48.99, compared with its previous close of $49.36. In the last trading session, the stock traded between $46.98 and $48.99. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Arrowhead Pharmaceuticals is now worth
$ 62.22
Resulting in a loss of
$ 37.78 (37.78%)
Note: Past profits do not guarantee future returns.
Rating from 11 Analysts
Today's Change
$-2.21 (-4.48%)
Day High
$48.99
Day Low
$46.98
Day Open
$48.99
Prev Close
$49.36
Volume
16,45,585
1W Return
-23.55%
1M Return
-22.40%
3M Return
-47.15%
6M Return
-39.35%
1Y Return
13.62%
Market Cap ($ Mn)
6,660
PE Ratio
-
PB Ratio
25.74
PEG Ratio
-
ROE
7.88%
ROCE
9.11%
EPS (TTM)
$-1.38
1 Week
-23.55%
1 Month
-22.40%
3 Months
-47.15%
6 Months
-39.35%
9 Months
-23.39%
Arrowhead Pharmaceuticals reports $724M net loss for FY26
Net loss widened to $724.2 million in FY26 from $1.6 million in FY25. Revenue declined to $450.8 million from $829.4 million in the prior year. REDEMPLO new-to-brand prescriptions grew 63% quarter over quarter. Company secured $400 million term loan at reduced interest rates.
TodayArrowhead Pharmaceuticals reports 78% drop in pancreatitis events
Plozasiran reduced acute pancreatitis event rates by 78% overall and 91% in high-risk patients versus placebo. PALISADE extension showed sustained triglyceride and APOC3 reductions through up to 36 months of treatment. ARO-DIMER-PA single doses lowered LDL-C by up to 65% and triglycerides by up to 78% in Phase 1/2a trial. Pooled SHASTA-3/4 safety profile showed similar adverse event rates between treatment and placebo groups.
3 days agoArrowhead Pharmaceuticals to webcast FY26 results on November 12
Arrowhead Pharmaceuticals will host a webcast on November 12, 2026. The call covers financial results for FY26 ending September 30, 2026. Live audio available via the company's investor relations website. Analysts must register for dial-in details and PIN codes.
9 days agoHC Wainwright reiterates Buy rating on Arrowhead Pharma with $120 target
HC Wainwright & Co. reiterated a Buy rating on Arrowhead Pharmaceuticals. Price target maintained at $120 per share. Analyst Patrick R. Trucchio issued the rating.
28 days agoArrowhead Pharmaceuticals reports 73% tau reduction with ARO-MAPT
Mean CSF total tau reduced by 73% at Day 105 in healthy volunteers. First clinical validation of siRNA delivery across blood-brain barrier. Maximum individual tau reduction reached 85% at 12.8 mg/kg dose. Sustained effect supports potential quarterly dosing schedule.
29 days agoArrowhead's ARO-DIMER-PA cuts LDL-C by 54% in early trial
ARO-DIMER-PA achieved 72% PCSK9 and 88% APOC3 gene silencing. Single-dose treatment reduced LDL-C by 54% and triglycerides by 73%. Non-HDL cholesterol fell 61% while Apolipoprotein B dropped 50%. Stock trades at $71.15 against a $102.09 average analyst target.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Arrowhead Pharmaceuticals is now worth
$ 62.22
Resulting in a loss of
$ 37.78 (37.78%)
Note: Past profits do not guarantee future returns.
